Effect of General Anesthesia Method on Cardiac Risk Patients on Ischemia Modified Markers
1 other identifier
interventional
70
0 countries
N/A
Brief Summary
To examine the effects of the general anesthesia method chosen in non-cardiac surgical operations of patients with cardiac risk on the levels of cardiac markers
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Dec 2022
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 6, 2022
CompletedFirst Posted
Study publicly available on registry
December 22, 2022
CompletedStudy Start
First participant enrolled
December 30, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
December 30, 2023
CompletedDecember 22, 2022
December 1, 2022
6 months
September 6, 2022
December 14, 2022
Conditions
Outcome Measures
Primary Outcomes (2)
comparing serum levels of ischemia modified albumin
serum levels of ischemia modified albumin (in terms of IU/ML)
intraoperative period
comparing serum levels of heart fatty acid binding protein
serum levels of heart fatty acid binding protein (in terms of mcg/L)
intraoperative period
Secondary Outcomes (1)
The effect of anesthesia method used in cardiac risk patients in terms of ephedrine consumption
intraoperative period
Study Arms (2)
GROUP TIVA
ACTIVE COMPARATORAnesthesia will be maintained with propofol (6-10 mg/kg/hour) and remifentanil (0.1-0.3 μg/kg/min). Blood will be taken from the patients at 0, 1 and 4 hours, centrifuged and stored at -80 degrees. From these examples, CK, CKMB, HIGH SENSITIVE TROPONIN, HFABP, IMA AND ALBUMIN will be studied.
GROUP INHALATION ANESTHESIA
ACTIVE COMPARATORAnesthesia will be maintained with sevoflurane (2 ml/min) 50% oxygen and remifentanil (0.1-0.3 μg/kg/min). Blood will be taken from the patients at 0, 1 and 4 hours, centrifuged and stored at -80 degrees. From these examples, CK, CKMB, HIGH SENSITIVE TROPONIN, HFABP, IMA AND ALBUMIN will be studied.
Interventions
Anesthesia will be maintained with propofol (6-10 mg/kg/hour) and remifentanil (0.1-0.3 μg/kg/min).
Anesthesia will be maintained with sevoflurane (2 ml/min) 50% oxygen and remifentanil (0.1-0.3 μg/kg/min).
Eligibility Criteria
You may qualify if:
- Being 18 years or older
- Getting a score of 2 and above according to the Lee cardiac index
- Having a non-cardiac surgical procedure that will take at least three hours
- ASA II or III
You may not qualify if:
- Under 18 years old
- Those who refused to participate in the study
- Patients with chronic renal failure
- Patients with creatinine value ≥ 1.5 mg/dl
- Surgery that takes less than 3 hours
- Patients with liver failure
- Refusing to participate in the study
- Being allergic to the drugs used
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Canan Atalat
Ataturk University
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- SCREENING
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Clinical Professor
Study Record Dates
First Submitted
September 6, 2022
First Posted
December 22, 2022
Study Start
December 30, 2022
Primary Completion
June 30, 2023
Study Completion
December 30, 2023
Last Updated
December 22, 2022
Record last verified: 2022-12